Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six research firms that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the […]